Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
Open Access
- 19 June 2007
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 97 (2), 177-182
- https://doi.org/10.1038/sj.bjc.6603851
Abstract
Altered histone deacetylase (HDAC) activity has been identified in several types of cancer. This study was designed to determine the safety and maximum tolerated dose (MTD) of valproic acid (VPA) as an HDAC inhibitor in cancer patients. Twenty-six pre-treated patients with progressing solid tumours were enrolled in dose-escalating three-patient cohorts, starting at a dose of VPA 30 mg kg−1 day−1. VPA was administered as an 1-h infusion daily for 5 consecutive days in a 21-day cycle. Neurocognitive impairment dominated the toxicity profile, with grade 3 or 4 neurological side effects occurring in 8 out of 26 patients. No grade 3 or 4 haematological toxicity was observed. The MTD of infusional VPA was 60 mg kg−1 day−1. Biomonitoring of peripheral blood lymphocytes demonstrated the induction of histone hyperacetylation in the majority of patients and downmodulation of HDAC2. Pharmacokinetic studies showed increased mean and maximum serum VPA concentrations >120 and >250 mg l−1, respectively, in the 90 and 120 mg kg−1 cohorts, correlating well with the incidence of dose-limiting toxicity (DLT). Neurotoxicity was the main DLT of infusional VPA, doses up to 60 mg kg−1 day−1 for 5 consecutive days are well tolerated and show detectable biological activity. Further investigations are warranted to evaluate the effectivity of VPA alone and in combination with other cytotoxic drugs.Keywords
This publication has 23 references indexed in Scilit:
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.2002
- Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsThe EMBO Journal, 2001
- Histone deacetylase inhibitors as new cancer drugsCurrent Opinion in Oncology, 2001
- A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.2001
- Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and TeratogenJournal of Biological Chemistry, 2001
- Histone acetylation and diseaseCellular and Molecular Life Sciences, 2001
- Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed CellsJNCI Journal of the National Cancer Institute, 2000
- Histone Acetylation Modifiers in the Pathogenesis of Malignant DiseaseMolecular Medicine, 2000
- The language of covalent histone modificationsNature, 2000